Literature DB >> 22171087

Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder.

A Mørk1, A Pehrson, L T Brennum, S Møller Nielsen, H Zhong, A B Lassen, S Miller, L Westrich, N J Boyle, C Sánchez, C W Fischer, N Liebenberg, G Wegener, C Bundgaard, S Hogg, B Bang-Andersen, T Bryan Stensbøl.   

Abstract

1-[2-(2,4-Dimethylphenyl-sulfanyl)-phenyl]-piperazine (Lu AA21004) is a human (h) serotonin (5-HT)(3A) receptor antagonist (K(i) = 3.7 nM), h5-HT(7) receptor antagonist (K(i) = 19 nM), h5-HT(1B) receptor partial agonist (K(i) = 33 nM), h5-HT(1A) receptor agonist (K(i) = 15 nM), and a human 5-HT transporter (SERT) inhibitor (K(i) = 1.6 nM) (J Med Chem 54:3206-3221, 2011). Here, we confirm that Lu AA21004 is a partial h5-HT(1B) receptor agonist [EC(50) = 460 nM, intrinsic activity = 22%] using a whole-cell cAMP-based assay and demonstrate that Lu AA21004 is a rat (r) 5-HT(7) receptor antagonist (K(i) = 200 nM and IC(50) = 2080 nM). In vivo, Lu AA21004 occupies the r5-HT(1B) receptor and rSERT (ED(50) = 3.2 and 0.4 mg/kg, respectively) after subcutaneous administration and is a 5-HT(3) receptor antagonist in the Bezold-Jarisch reflex assay (ED(50) = 0.11 mg/kg s.c.). In rat microdialysis experiments, Lu AA21004 (2.5-10.0 mg/kg s.c.) increased extracellular 5-HT, dopamine, and noradrenaline in the medial prefrontal cortex and ventral hippocampus. Lu AA21004 (5 mg/kg per day for 3 days; minipump subcutaneously), corresponding to 41% rSERT occupancy, significantly increased extracellular 5-HT in the ventral hippocampus. Furthermore, the 5-HT(3) receptor antagonist, ondansetron, potentiated the increase in extracellular levels of 5-HT induced by citalopram. Lu AA21004 has antidepressant- and anxiolytic-like effects in the rat forced swim (Flinders Sensitive Line) and social interaction and conditioned fear tests (minimal effective doses: 7.8, 2.0, and 3.9 mg/kg). In conclusion, Lu AA21004 mediates its pharmacological effects via two pharmacological modalities: SERT inhibition and 5-HT receptor modulation. In vivo, this results in enhanced release of several neurotransmitters and antidepressant- and anxiolytic-like profiles at doses for which targets in addition to the SERT are occupied. The multimodal activity profile of Lu AA21004 is distinct from that of current antidepressants.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22171087     DOI: 10.1124/jpet.111.189068

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  77 in total

1.  A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment.

Authors:  Marina Sagud; Matea Nikolac Perkovic; Bjanka Vuksan-Cusa; Anja Maravic; Dubravka Svob Strac; Alma Mihaljevic Peles; Maja Zivkovic; Zorana Kusevic; Nela Pivac
Journal:  Psychopharmacology (Berl)       Date:  2016-06-29       Impact factor: 4.530

Review 2.  A brief history of the development of antidepressant drugs: from monoamines to glutamate.

Authors:  Todd M Hillhouse; Joseph H Porter
Journal:  Exp Clin Psychopharmacol       Date:  2015-02       Impact factor: 3.157

Review 3.  Diagnosis and treatment of depression and cognitive impairment in late life.

Authors:  Sarah Shizuko Morimoto; Dora Kanellopoulos; Kevin J Manning; George S Alexopoulos
Journal:  Ann N Y Acad Sci       Date:  2015-02-05       Impact factor: 5.691

Review 4.  Vortioxetine: a review of its use in major depressive disorder.

Authors:  Karly P Garnock-Jones
Journal:  CNS Drugs       Date:  2014-09       Impact factor: 5.749

5.  Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output.

Authors:  Christoph van Amsterdam; Christoph A Seyfried
Journal:  Psychopharmacology (Berl)       Date:  2014-01-14       Impact factor: 4.530

6.  Response of Htr3a knockout mice to antidepressant treatment and chronic stress.

Authors:  Vincent Martin; Armance Riffaud; Tevrasamy Marday; Charly Brouillard; Bernard Franc; Jean-Pol Tassin; Caroline Sevoz-Couche; Raymond Mongeau; Laurence Lanfumey
Journal:  Br J Pharmacol       Date:  2017-07-05       Impact factor: 8.739

7.  Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression.

Authors:  Kristian Gaarn du Jardin; Nico Liebenberg; Heidi Kaastrup Müller; Betina Elfving; Connie Sanchez; Gregers Wegener
Journal:  Psychopharmacology (Berl)       Date:  2016-05-28       Impact factor: 4.530

8.  Vortioxetine: first global approval.

Authors:  Andrew Gibb; Emma D Deeks
Journal:  Drugs       Date:  2014-01       Impact factor: 9.546

Review 9.  Serotonin and beyond: therapeutics for major depression.

Authors:  Pierre Blier; Mostafa El Mansari
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-02-25       Impact factor: 6.237

10.  Future directions for serotonin and antidepressants.

Authors:  Francesc Artigas
Journal:  ACS Chem Neurosci       Date:  2013-01-16       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.